Hiv vaccine market driven by preclinical research in immunology
Upcoming SlideShare
Loading in...5
×
 

Hiv vaccine market driven by preclinical research in immunology

on

  • 13 views

“HIV Vaccine Market Opportunity & Clinical Pipeline Analysis” Report Highlights: ...

“HIV Vaccine Market Opportunity & Clinical Pipeline Analysis” Report Highlights:

Introduction to HIV Vaccine & Mechanism
Global HIV Incidence Scenario
R&D Funding Scenario for HIV Vaccine
FDA Regulatory Framework
HIV Vaccine Clinical Trial by Phase & Country
HIV Vaccines in Development Phase: More Than 100
Most HIV Vaccines in Preclinical Phase: More Than 50
Discontinued & Suspended HIV Vaccines Profiles

Statistics

Views

Total Views
13
Views on SlideShare
13
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Hiv vaccine market driven by preclinical research in immunology Hiv vaccine market driven by preclinical research in immunology Document Transcript

  • HIV Vaccine Market Driven By Preclinical Research In Immunology “HIV Vaccine Market Opportunity & Clinical Pipeline Analysis” Report Highlights:  Introduction to HIV Vaccine & Mechanism  Global HIV Incidence Scenario  R&D Funding Scenario for HIV Vaccine  FDA Regulatory Framework  HIV Vaccine Clinical Trial by Phase & Country  HIV Vaccines in Development Phase: More Than 100  Most HIV Vaccines in Preclinical Phase: More Than 50  Discontinued & Suspended HIV Vaccines Profiles There have been significant breakthroughs achieved in terms of prevention and treatment of HIV and AIDS in the past 3-4 years. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and an efficient vaccine, with the help of adequate funding. Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future. In terms of the market, with the rising popularity of this disease and the growing efforts to combat its spread, it is most likely that an increasing number of companies would enter this market, which would, in the long run, reduce the overall cost of drugs owing to increased competition among the players. Additionally, economies of scale would also be a major factor driving down the cost of drugs targeted for the HIV virus infected people. This in turn would make the drugs and treatment options more affordable. The HIV vaccine market in the future would witness an increased level of focus on basic and preclinical research in immunology owing to the fact that this would provide the necessary knowledge to guide the design of an effective HIV-1 vaccine. With basic research, the scientists could get a deeper understanding of the process of immune response in certain HIV-1 infected persons. However, the complete use of this knowledge in achieving the ultimate research objective of developing an effective vaccine is still questionable. For Report Sample Visit: “HIV Vaccine Market Opportunity & Clinical Pipeline Analysis” Or Contact: avinash@kuickresearch.com